CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.06
1.32%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 20:00

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

CureVac NV ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.02
Open* 3.07
1-Year Change* -53.83%
Day's Range* 3.05 - 3.14
52 wk Range 3.41-12.48
Average Volume (10 days) 1.02M
Average Volume (3 months) 21.99M
Market Cap 815.08M
P/E Ratio -100.00K
Shares Outstanding 223.92M
Revenue 46.63M
EPS -1.51
Dividend (Yield %) N/A
Beta 2.60
Next Earnings Date Apr 23, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 3.02 0.06 2.03% 2.96 3.05 2.87
Mar 26, 2024 2.92 -0.19 -6.11% 3.11 3.23 2.87
Mar 25, 2024 3.12 0.14 4.70% 2.98 3.16 2.98
Mar 22, 2024 3.02 0.03 1.00% 2.99 3.10 2.97
Mar 21, 2024 3.00 0.08 2.74% 2.92 3.06 2.91
Mar 20, 2024 3.02 0.25 9.03% 2.77 3.02 2.73
Mar 19, 2024 2.90 -0.21 -6.75% 3.11 3.18 2.90
Mar 18, 2024 3.18 -0.05 -1.55% 3.23 3.26 3.16
Mar 15, 2024 3.27 0.02 0.62% 3.25 3.32 3.23
Mar 14, 2024 3.31 0.02 0.61% 3.29 3.34 3.22
Mar 13, 2024 3.33 0.04 1.22% 3.29 3.48 3.29
Mar 12, 2024 3.37 -0.01 -0.30% 3.38 3.45 3.24
Mar 11, 2024 3.33 -0.07 -2.06% 3.40 3.56 3.29
Mar 8, 2024 3.40 0.12 3.66% 3.28 3.48 3.28
Mar 7, 2024 3.29 0.04 1.23% 3.25 3.32 3.23
Mar 6, 2024 3.25 0.01 0.31% 3.24 3.32 3.24
Mar 5, 2024 3.30 0.04 1.23% 3.26 3.34 3.24
Mar 4, 2024 3.35 -0.03 -0.89% 3.38 3.40 3.23
Mar 1, 2024 3.39 0.05 1.50% 3.34 3.50 3.34
Feb 29, 2024 3.39 -0.04 -1.17% 3.43 3.51 3.35

CureVac N.V. Events

Time (UTC) Country Event
Tuesday, April 23, 2024

Time (UTC)

06:30

Country

US

Event

Q4 2023 CureVac NV Earnings Release
Q4 2023 CureVac NV Earnings Release

Forecast

-

Previous

-
Tuesday, May 21, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 CureVac NV Earnings Release
Q1 2024 CureVac NV Earnings Release

Forecast

-

Previous

-
Tuesday, June 18, 2024

Time (UTC)

12:00

Country

US

Event

CureVac NV Annual Shareholders Meeting
CureVac NV Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 67.42 102.99 48.871 17.416 12.871
Revenue 67.42 102.99 48.871 17.416 12.871
Cost of Revenue, Total 159.045 238.195 14.173 27.983 17.744
Gross Profit -91.625 -135.205 34.698 -10.567 -4.873
Total Operating Expense 316.877 515.253 158.686 116.914 85.695
Selling/General/Admin. Expenses, Total 95.264 93.164 48.169 48.367 24.644
Research & Development 53.9 811.648 111.23 42.768 40.579
Depreciation / Amortization 20.346 13.24 8.696 2.831 2.873
Other Operating Expenses, Total -36.186 -574.6 -23.582 -5.035 -0.145
Operating Income -249.457 -412.263 -109.815 -99.498 -72.824
Interest Income (Expense), Net Non-Operating 0.302 -0.235 -20.033 -0.627 1.693
Net Income Before Taxes -249.155 -412.498 -129.848 -100.125 -71.131
Net Income After Taxes -249.029 -411.716 -129.122 -99.873 -71.241
Net Income Before Extra. Items -249.029 -411.716 -129.122 -99.873 -71.241
Net Income -249.029 -411.716 -129.122 -99.873 -71.241
Income Available to Common Excl. Extra. Items -249.029 -411.716 -129.122 -99.873 -71.241
Income Available to Common Incl. Extra. Items -249.029 -411.716 -129.122 -99.873 -71.241
Diluted Net Income -249.029 -411.716 -129.122 -99.873 -71.241
Diluted Weighted Average Shares 194.997 187.121 180.461 176.46 176.46
Diluted EPS Excluding Extraordinary Items -1.27709 -2.20027 -0.71551 -0.56598 -0.40372
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.17342 -2.35167 -0.71551 -0.56598 -0.40372
Unusual Expense (Income) 24.508 -66.394
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 7.579 7.129 11.689 11.212 20.146
Revenue 7.579 7.129 11.689 11.212 20.146
Cost of Revenue, Total 25.855 20.634 80.001 24.079 42.681
Gross Profit -18.276 -13.505 -68.312 -12.867 -22.535
Total Operating Expense 79.381 67.484 133.199 63.592 80.445
Selling/General/Admin. Expenses, Total 20.682 21.005 24.937 23.988 24.492
Research & Development 29.084 22.526 22.832 10.765 10.53
Depreciation / Amortization 4.754 4.831 6.998 5.106 4.274
Unusual Expense (Income) -0.413 -0.31 -0.063 -0.273 -0.035
Other Operating Expenses, Total -0.581 -1.202 -1.506 -0.073 -1.497
Operating Income -71.802 -60.355 -121.51 -52.38 -60.299
Interest Income (Expense), Net Non-Operating 4.414 2.937 -7.24 4.734 2.729
Net Income Before Taxes -67.388 -57.418 -128.75 -47.646 -57.57
Net Income After Taxes -67.414 -57.419 -128.784 -47.568 -57.584
Net Income Before Extra. Items -67.414 -57.419 -128.784 -47.568 -57.584
Net Income -67.414 -57.419 -128.784 -47.568 -57.584
Income Available to Common Excl. Extra. Items -67.414 -57.419 -128.784 -47.568 -57.584
Income Available to Common Incl. Extra. Items -67.414 -57.419 -128.784 -47.568 -57.584
Diluted Net Income -67.414 -57.419 -128.784 -47.568 -57.584
Diluted Weighted Average Shares 223.883 212.663 216.34 189.565 187.052
Diluted EPS Excluding Extraordinary Items -0.30111 -0.27 -0.59529 -0.25093 -0.30785
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.30231 -0.27095 -0.59547 -0.25187 -0.30797
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 584.029 940.019 1389.85 57.175 73.07
Cash and Short Term Investments 497.733 813.4 1323.02 31.114 60.404
Cash & Equivalents 495.797 811.464 1322.59 30.684 21.38
Short Term Investments 1.936 1.936 0.43 0.43 39.024
Total Receivables, Net 11.553 21.216 4.011 18.714 8.848
Accounts Receivable - Trade, Net 9.002 18.504 1.822 17.153 6.858
Total Inventory 23.989 56.159 14.531 6.197 2.951
Prepaid Expenses 4.507 5.724 40.054 1.15 0.421
Other Current Assets, Total 46.247 43.52 8.235 0.446
Total Assets 860.472 1158.24 1511.36 130.62 125.659
Property/Plant/Equipment, Total - Net 241.702 200.393 100.589 61.686 40.472
Property/Plant/Equipment, Total - Gross 271.27 247.412 145.054 84.931 58.497
Accumulated Depreciation, Total -29.568 -47.019 -44.466 -23.245 -18.025
Intangibles, Net 19.315 13.238 14.146 5.698 6.213
Note Receivable - Long Term 0.302 1.08 1.034 0.966 0.749
Other Long Term Assets, Total 2.661 3.512 5.733 5.095 5.155
Total Current Liabilities 156.225 357.734 247.622 28.086 28.13
Accounts Payable 73.463 127.703 21.685 5.331 9.029
Accrued Expenses 39.289 46.802 50.022 12.068 12.258
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4.98 3.469 3.234 2.004 0.077
Other Current Liabilities, Total 38.493 179.76 172.681 8.683 6.766
Total Liabilities 327.219 469.766 800.009 173.422 93.576
Total Long Term Debt 37.106 25.423 52.042 77.144 0
Long Term Debt 0 25.189 65.018 0
Capital Lease Obligations 37.106 25.423 26.853 12.126 0
Deferred Income Tax 0 1.623 0
Other Liabilities, Total 133.888 86.609 500.345 66.569 65.446
Total Equity 533.253 688.476 711.347 -42.802 32.083
Common Stock 23.4 22.454 21.655 0.727 0.727
Retained Earnings (Accumulated Deficit) 511.473 671.873 689.635 -43.551 31.366
Other Equity, Total -0.139 -0.034 0.057 0.022 -0.01
Total Liabilities & Shareholders’ Equity 860.472 1158.24 1511.36 130.62 125.659
Total Common Shares Outstanding 194.958 187.121 180.461 176.46 176.46
Treasury Stock - Common -1.481 -5.817
Goodwill, Net 12.463
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 536.833 603.21 686.916 584.029 622.282
Cash and Short Term Investments 467.6 543.279 620.588 500.284 543.464
Cash & Equivalents 464.145 537.925 617.519 495.797 540.865
Short Term Investments 3.455 5.354 3.069 4.487 2.599
Total Receivables, Net 10.594 6.562 5.843 9.002 6.17
Accounts Receivable - Trade, Net 10.594 6.562 5.843 9.002 6.17
Total Inventory 23.3 22.194 24.678 23.989 7.868
Prepaid Expenses 25.453 21.221 25.597 40.287 60.952
Other Current Assets, Total 9.886 9.954 10.21 10.467 3.828
Total Assets 842.566 899.48 973.672 860.472 910.512
Property/Plant/Equipment, Total - Net 272.217 261.57 253.163 241.702 251.461
Intangibles, Net 30.469 31.7 30.6 31.778 33.775
Other Long Term Assets, Total 3.047 3 2.993 2.963 2.994
Total Current Liabilities 150.679 156.276 90.298 156.225 172.352
Payable/Accrued 12.57 13.419 14.973 73.463 52.608
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.534 5.205 5.058 4.98 4.652
Other Current Liabilities, Total 132.575 137.652 70.267 77.782 115.092
Total Liabilities 240.301 250.433 260.273 327.219 285.524
Total Long Term Debt 36.58 35.276 36.087 37.106 36.609
Long Term Debt
Capital Lease Obligations 36.58 35.276 36.087 37.106 36.609
Other Liabilities, Total 53.042 58.881 133.888 133.888 76.563
Total Equity 602.265 649.047 713.399 533.253 624.988
Common Stock 26.871 26.866 26.862 23.4 22.834
Retained Earnings (Accumulated Deficit) 575.547 622.304 687.001 511.473 604.286
Treasury Stock - Common 0 0 -0.344 -1.481 -1.734
Other Equity, Total -0.153 -0.123 -0.12 -0.139 -0.398
Total Liabilities & Shareholders’ Equity 842.566 899.48 973.672 860.472 910.512
Total Common Shares Outstanding 223.924 223.873 223.819 194.958 190.244
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -249.155 -412.498 -129.848 -100.125 -71.131
Cash From Operating Activities -286.177 -733.128 522.403 -86.963 -74.11
Cash From Operating Activities 23.741 15.674 10.671 7.164 3.781
Non-Cash Items 67.744 -350.082 40.194 20.432 -5.889
Cash Taxes Paid 0.128 0.502 0.093 0.345 0.026
Changes in Working Capital -128.511 15.361 602.482 -14.434 -0.871
Cash From Investing Activities -93.499 -127.901 -45.274 28.181 -4.264
Capital Expenditures -93.222 -127.901 -47.352 -12.224 -14.723
Other Investing Cash Flow Items, Total -0.277 0 2.078 40.405 10.459
Cash From Financing Activities 63.173 344.964 819.833 67.979 -0.112
Issuance (Retirement) of Debt, Net -4.221 -28.183 -47.884 67.979 -0.112
Foreign Exchange Effects 0.836 4.936 -5.053 0.107 0.213
Net Change in Cash -315.667 -511.129 1291.91 9.304 -78.273
Cash Interest Paid 4.606 9.785 8.694 0.824
Deferred Taxes 0.004 -1.583 -1.096
Issuance (Retirement) of Stock, Net 0.91 373.147 867.717
Financing Cash Flow Items 66.484
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -57.418 -249.155 -120.405 -72.759 -15.189
Cash From Operating Activities -99.586 -286.177 -237.091 -201.175 -136.511
Cash From Operating Activities 5.853 23.741 23.349 16.651 9.077
Deferred Taxes 0.002 0.004 0.049 -0.01
Non-Cash Items -0.347 67.744 -14.466 -20.765 -13.72
Cash Taxes Paid 0.004 0.128 0.152 0.126
Cash Interest Paid 0.633 4.606 3.326 2.608 1.33
Changes in Working Capital -47.676 -128.511 -125.618 -124.292 -116.679
Cash From Investing Activities -13.162 -93.499 -72.559 -44.715 -17.185
Capital Expenditures -13.162 -93.222 -72.559 -44.715 -17.185
Other Investing Cash Flow Items, Total -0.277
Cash From Financing Activities 234.709 63.173 29.873 3.409 -0.46
Issuance (Retirement) of Stock, Net 235.969 0.91 0.635 0.631 0.44
Issuance (Retirement) of Debt, Net -1.26 -4.221 -3.087 -1.943 -0.9
Foreign Exchange Effects -0.239 0.836 9.178 4.583 0.895
Net Change in Cash 121.722 -315.667 -270.599 -237.898 -153.261
Financing Cash Flow Items 66.484 32.325 4.721

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

CureVac N.V. Company profile

CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).

The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’

CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.

The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.

CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.

According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.

According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.

You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.

Industry: Biotechnology & Medical Research (NEC)

Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,206.90 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

ETH/USD

3,578.63 Price
+1.900% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,968.45 Price
+3.000% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.63 Price
+1.260% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading